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Abstract 
Bronchiectasis is a condition characterized by pathological dilation of the airways.  More 
specifically, the radiographic demonstration of airways enlargement is the common feature of a 
heterogeneous set of conditions and clinical presentations.  There are no approved therapies for 
the condition other than for bronchiectasis caused by cystic fibrosis.  The heterogeneity of 
bronchiectasis is the major challenge in clinical practice and the major reason for difficulty in 
achieving endpoints in clinical trials. Recent observations have improved our knowledge 
regarding bronchiectasis such that it may be more effective to describe patients according to a 
heterogeneous group of endotypes, defined by a distinct functional or pathobiological 
mechanism, or clinical phenotypes, defined by relevant and common features of disease. In 
doing so, we may finally develop more specific therapies needed to effectively treat our patients. 
Here we describe some of the recent advances in endotyping, genetics and disease heterogeneity 
of bronchiectasis including observations related to the microbiome. 
Bronchiectasis is defined as permanent enlargement of the airways 1, a condition with its 
own ICD-10 CM diagnostic code (i.e. J47.9) and mostly the result of an intrinsic airways 
pathology resulting in dilation. There are multiple etiologies of bronchiectasis and a broad array 
of clinical presentations.2 The extent of bronchiectasis can range from focal disease, limited to 
one segment or lobe, to diffuse disease, involving both lungs in all lobes.  The bronchiectatic 
findings range from subtle dilation to cystic changes in the airways.  Some patients will be 
asymptomatic and the bronchiectasis is discovered unexpectedly while others suffer daily 
symptoms of cough and sputum production with periodic worsening of their symptoms known as 
exacerbations.3 The diagnosis of bronchiectasis is increasing worldwide. Previously classified as 
a rare or orphan disease, bronchiectasis has now been reported at rates up to 566 per 100,000 
population with a prevalence that has increased 40% in the past 10 years.4 
Despite having its own diagnostic code, there are no medications or therapies approved 
by regulatory authorities in the United States or Europe for this indication.  The exception is the 
bronchiectasis due to cystic fibrosis (CF), for which there are several approved medications, but 
none have had their label expanded to include other causes of bronchiectasis.5 Yet there are 
guidelines that recommend treatments for bronchiectasis5, and reports of therapies have been 
demonstrated to associate with clinical benefit 6, 7, suggesting that only some patients with 
bronchiectasis are likely to benefit from those therapies.8, 9 The pathway to more precise 
treatment will require a greater understanding of our patients beyond a mere imaging study.  
What follows is a review of recent studies that have attempted to better describe patients 
according to a heterogeneous group of endotypes, defined by a distinct functional or 
pathobiological mechanism10, or clinical phenotypes, defined by relevant and common features 
of disease.11 It is hoped that this approach to better understand our patients with bronchiectasis 
may finally provide us with the knowledge needed to more effectively treat them.  
 
Pathophysiology of disease 
The list of conditions known to cause or be associated with bronchiectasis is long but 
most can be found to have common features leading to the remodeling of the airways and 
dilation.  A useful pathophysiologic pathway has been described as a cycle of events promoting 
impaired mucociliary clearance and retention of airways secretions that disrupt the normal host 
defenses and render the airways more vulnerable to establishment of chronic infection. The 
persistence of bacterial pathogens incites an inflammatory response that results in injury and 
abnormal remodeling of the airways leading to bronchiectasis.  Each step begets the next, 
resulting in a persistent and progressive process over time.  This model has worked well to 
describe how many conditions enter into the cycle; CF and primary ciliary dyskinesia (PCD) 
have impaired mucociliary clearance; immunodeficiency can result in recurrent and persistent 
infection; injury to the airways, either because of severe infection or mechanical injury (e.g. 
toxic inhalation or chronic aspiration) can result in an impaired healing of the airways, and so on. 
However, interactions are far more complex, each pathophysiologic step contributing to all 
others perhaps better described as a vortex (Figure 1).  
How this pathophysiologic model results in dilation of the airways and why there is such 
heterogeneity in extent of disease are less well understood. A simple explanation is that impaired 
mucociliary function results in an accumulation of material that obstructs and stents the airway 
while remodeling occurs.  Another hypothesis can be found in the study of polycystic kidney 
disease (PKD) in which a non-motile ciliary abnormality in renal epithelial cells results in 
cellular hypertrophy and hyperplasia, and cyst formation.12 Since patients with PKD also have 
bronchiectasis13, this suggests there may be a link between cilia, cellular signaling processes, and 
bronchiectasis.  An animal ciliary knockout model of PKD demonstrated loss of airway motile 
cilia as well as bronchial remodeling in the absence of inflammation but with proliferation of 
facultative progenitor cells.14 Such a role for ciliary function may offer a commonality among 
the varied etiologies of bronchiectasis.  
The radiographic features help to explain why some patients will have focal disease (e.g. 
because of severe injury) rather than diffuse (e.g. PCD), or why some have disease in the lower 
lobes (e.g. recurrent aspiration). While some diagnoses have easily available and interpretable 
diagnostic testing (e.g. CF), others are less easily established, and yet this may still not be 
sufficient in defining which patients are likely to respond to specific therapies.  Alternative 
characteristics (e.g. genotyping or biomarkers) may better characterize patients to understand 
how best to develop and use therapies. 
 
Endotypes and genotypes 
While the largest group of patients will have the diagnosis of idiopathic bronchiectasis 
for lack of a specific etiology, reviewing those conditions with well-known, genetics-based 
pathways offers insights into understanding the underlying mechanisms of bronchiectasis 
pathogenesis and development of specific treatment regimens.  However, the interaction between 
genetics, endotypes, environment, and therapeutic interventions can vary. In asthma, for 
example, studies focused on genetic risk loci have not yielded a clear pathway to therapeutic 
intervention, while classification based on inflammatory endotypes can correlate with effective, 
specific anti-inflammatory therapies. 15 
 Cystic Fibrosis (CF) 
CF serves as the prime example of how disease categorization based on genotype can 
drive effective therapeutic intervention.  CF is primarily a disorder of mucociliary clearance 
caused by altered epithelial ion transport.  There are well characterized biomarkers, such as 
sweat chloride and transepithelial potential difference assays, that have been useful in the 
diagnosis and research assessment of therapeutic response.  Discovery of the causative gene for 
CF in 1989 led to increasing knowledge of the protein product, cystic fibrosis transmembrane 
conductance regulator (CFTR), including its structure, function, and the protein synthesis 
pathway from nucleus to insertion and proper functioning in the epithelial apical membrane. 16, 17 
The correlation between specific genetic mutations and their impact on CFTR quantity and 
function has led to remarkable genotype-specific treatment (https://www.cff.org/Trials/Pipeline) 
that can significantly improve the clinical course of bronchiectasis and other manifestations of 
disease (Figure 2).  While the airway dilation may remain, airway inflammation, secretion 
clearance, and control of infection can all improve with CFTR modulator therapy. 18, 19 
 
Primary Ciliary Dyskinesia (PCD) 
PCD is another genetic disorder of mucociliary clearance characterized by disordered 
function of motile cilia. Bedside measurement of nitric oxide (NO) production is a useful 
biomarker of ciliary motility, 20 but it must be emphasized that PCD genotypes associated with 
normal nasal NO have been described. 21 Measurement of nasal NO production and high-speed 
video assessment of ciliary beat characteristics may be useful markers of drug efficacy in future 
clinical trials. 22 In contrast to the monogenic etiology of CF, the assembly and regulation of 
ciliary proteins is under the control of multiple genes. 23 While electron microscopic examination 
of cross-sectional cilia anatomy lacks sufficient sensitivity and specificity to be a useful 
diagnostic test, correlation has been noted in research settings between mutated genes and 
structural abnormalities (Figure 3). As drug development for PCD advances, this 
genotype/structure-function relationship may prove useful for drug targeting similar to the path 
that CFTR modulator therapeutics development has taken in CF.   
 
Immune Deficiencies 
Bronchiectasis is a common manifestation of many primary immune deficiencies (PID) 
and disorders of immune regulation. These conditions can be subdivided based roughly on the 
primary immune cells of origin.  Biomarkers that can be useful in diagnosis and assessment of 
treatment include lymphocyte phenotyping with delineation of T, B, and NK cell numbers, 
quantitative immunoglobulin levels, and specific antibody responses to protein and 
polysaccharide antigens.  Humoral immune deficiencies account for approximately 70% of all 
primary immune deficiencies and the majority of PID-associated causes of bronchiectasis. 24 
While abnormally low immunoglobulin levels may point toward this subgroup, knowledge of the 
underlying genetic causes are of increasing importance for directing specific therapies or for 
early identification of patients who would benefit from bone marrow transplantation. Common 
variable immune deficiency, the most commonly diagnosed immunodeficiency characterized by 
significant reductions in IgG and IgA or IgM and presentation later in life with recurrent 
pyogenic sinopulmonary infections, is clinically and genetically a heterogeneous disorder. 25  X-
linked agammaglobulinemia (XLA) is caused by mutations in the Bruton tyrosine kinase (BTK) 
gene and can result in a profound humoral immunodeficiency. 26 However, even XLA can have a 
variable clinical phenotype based on genotype with adults having a higher proportion of splice-
site mutations and lower proportion of frameshift mutations than children with XLA. 27 The 
autosomal dominant hyperimmunoglobulin E syndrome (AD-HIES or Job’s syndrome) is 
another example of a rare PID that may be identified by its characteristic markedly elevated IgE 
levels and clinical findings of eczema, recurrent skin and pulmonary infections, skeletal 
abnormalities and coarse facial features.  However, with this disease, the high IgE is more of a 
disease marker than a pathway indicator.  This disease has been better defined by identification 
of mutations in the signal transduction and activator of transcription 3 (STAT3) gene. 28 STAT3 
is important for several key airway defense mechanisms including TH17-based cytokine 
signaling leading to upregulation of antimicrobial peptides.  It is also felt to play a role in proper 
remodeling after epithelial injury by directing differentiation of airway basal cells into ciliated 
cells and away from mucus secreting epithelial cells. 29 Mutations in STAT3 affecting these 
pathways likely account for the high prevalence of bronchiectasis and cystic changes 
(pneumatoceles) seen in this disease. With the widespread availability of whole exome 
sequencing, it is likely that mutations in genes affecting immune function and regulation can 
account for unsuspected underlying systemic immune causes for patients with recurring 
respiratory tract infections leading to bronchiectasis with atypical late presentations and 
diagnosed in adulthood. 30, 31 
 
Autoimmune Diseases 
Several autoimmune diseases, most notably rheumatoid arthritis and inflammatory bowel 
disease, have been associated with bronchiectasis.  These conditions typically have predominant 
manifestations outside of the respiratory tract. Biomarkers such as rheumatoid factor, C-reactive 
protein, anti-nuclear cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies might 
be helpful in identifying these diseases in patients presenting with joint or bowel symptoms; they 
are not so helpful in characterizing the associated airway disease.  While infections may be 
common in bronchiectasis associated with these disorders, frequently the inflammatory 
component predominates.  In the case of ulcerative colitis associated bronchiectasis, the airway 
findings of cobblestoning, ulcerations and mucosal lymphoplasmocytic infiltration can mimic 
bowel findings.  These pulmonary manifestations may respond to anti-inflammatory agents such 
as inhaled or systemic steroids; however, some cases may require tumor necrosis factor alpha 
blockade (once infection is identified and controlled with antibiotics) or other immunodulatory 
drugs commonly used to treat bowel inflammation to control the progression of bronchiectasis. 32 
Causative genes have not been identified for these disorders.  For inflammatory bowel disease, 
associated genetic risk loci have been reported including CARD15/NOD2, ATG16L1, IRGM, 
IL23R, TNFSF15, and HLAD-QA1. Additional work is needed to know whether these correlate 
with airway manifestations and can lead to more specific therapeutic interventions. 33 
 
Allergic Bronchopulmonary Aspergillosis (ABPA) 
ABPA represents a unique overlap between immune dysregulation and obstructive 
airway diseases such as asthma and CF.  While it is associated with filamentous fungi in the 
airway, biomarkers of the allergic inflammatory response such as eosinophilia, total IgE, serum 
precipitans, and Aspergillus-specific IgE with IgG as a marker of A. fumigatus exposure are 
prominent in the diagnostic criteria. 34, 35 The bronchiectasis frequently is proximal and may have 
an exaggerated saccular, plugged appearance. A recent study comparing ABPA patients to atopic 
asthmatics and healthy controls, identified ABPA-associated SNPs in TLR3, IL4R, and IL13. 36 
These and other reported potential genetic susceptibility loci may be helpful in elucidating 
pathways and pointing to more specific therapies. 
 
COPD and Asthma 
The general relationship between asthma, COPD, and bronchiectasis remains unclear as 
to directionality of development. 37 Bronchiectasis can be seen in the setting of both asthma and 
COPD and has been associated with more advanced stages of these diseases.38, 39 Conversely as 
bronchiectasis progresses, increasing degrees of chronic airway obstruction can be seen and 
labeled as COPD and some patients with bronchiectasis may have eosinophilia, elevated IgE, 
and at least partially reversible airway obstruction suggesting an asthmatic component to their 
disease. Bronchiectasis has been historically under-recognized and so at least some of the 
overlap represents historic misdiagnosis. Endotyping to guide therapy has garnered much 
attention in asthma management and biomarkers (e.g. eosinophilia or increased IgE) may be 
useful in identifying patients with bronchiectasis who may benefit from directed anti-
inflammatory treatment.  The prime example of genetic overlap between COPD and 
bronchiectasis is alpha-1 antitrypsin deficiency in which there is a correlation between the 
biomarker of alpha-1 antitrypsin level, the genotype and disease severity. 
 
Idiopathic Bronchiectasis associated with NTM 
Since the late 1980s there has been increasing recognition of a population of patients with 
idiopathic bronchiectasis, many of whom are chronically infected with nontuberculous 
mycobacteria (NTM). 40 This group of patients are reported as predominantly post-menopausal, 
nonsmoking women with no known predisposing factors who present with chronic cough. 41 
They share characteristics with other endotypes, notably a high prevalence of CFTR mutations 
and evidence of ciliary dysfunction, 22, 42, 43 but they do not meet diagnostic criteria for CF or 
PCD.  Such observations suggest the etiology of the condition is likely to be multifactorial in 
which mucociliary clearance defects may play a key role.   
These patients have physical characteristics such as a tall, asthenic morphotype, scoliosis, 
pectus excavatum, mitral valve prolapse, and dural ectasia that overlap with heritable connective 
tissue disorders such as Marfan and Ehlers Danlos syndromes. 43, 44 Both bronchiectasis and 
pulmonary NTM infections have been noted in a well characterized population of these heritable 
connective tissue disorders. 45 Conversely, key characteristics such as bronchiectasis, NTM 
infection, and connective tissue disease features have been reported in a high proportion of 1st 
and 2nd degree relatives of carefully phenotyped idiopathic bronchiectasis patients with 
pulmonary NTM infections, strongly suggesting a genetic component to the disease. 45 Whole 
exome sequencing, using a candidate gene analysis of low frequency, potentially protein-altering 
variants, identified a significantly higher prevalence of variants in connective tissue disease 
associated genes and in mucociliary clearance associated (CFTR and cilia related) genes in 
NTM-affected probands and NTM-affected and unaffected family members compared to a 
healthy control reference population. 46 Many of the NTM-unaffected family members had 
bronchiectasis and/or connective tissue disease traits.  A higher prevalence of variants in genes 
related to systemic mycobacterial control distinguished those family members with pulmonary 
NTM from those without NTM.    Using a combination of phenotypic characteristics (tall, 
asthenic morphotype and dural ectasia), biomarkers (sweat chloride, nasal NO, ciliary beat 
frequency), and genetic analysis, it may be possible to fit patients with idiopathic bronchiectasis 
into key endotypes that may eventually point to a role for directed therapeutic interventions to 
address the underlying predisposing factors for disease development and progression.  
Theoretically, drugs which modulate CFTR function, ciliary beating characteristics, mitigate 
vascular and other sequelae of connective tissue disorders, or enhance relevant systemic immune 
pathways may alter host susceptibility and improve the disease course in patients with idiopathic 
bronchiectasis and chronic NTM infections (Figure 4).  
 
Disease heterogeneity beyond etiology: clinical phenotypes 
Evaluating patients with bronchiectasis requires knowledge of the heterogeneity of 
clinical presentation and variable clinical course. Patients with apparently mild symptoms at 
presentation may still have adverse prognostic factors and experience rapid progression of 
disease, while others with seemingly severe symptoms at the outset may be easily managed and 
with a good prognosis.47 A multidimensional approach to patient assessment will incorporate 
clinical history, physical examination, appropriate laboratory testing, microbiology and 
functional assessments. Some etiologies of bronchiectasis have specific clinical presentations or 
have characteristics that can suggest the underlying etiological diagnosis (Table 1) and inform 
use of diagnostic testing.48-50 However, many of these features remain non-specific and so efforts 
have been made to identify clinically recognizable sets of observable characteristics that link to 
clinical outcomes (i.e. clinical phenotypes).51 
Exacerbations of bronchiectasis, defined clinically as worsening of the usual respiratory 
symptoms 52, are significant events in the natural history of bronchiectasis. Patients with ≥3 
exacerbations per year had worse health status, were more likely to be hospitalized, and had 
increased mortality.53 Most importantly, the frequent exacerbator was identified as a true 
phenotype since the majority of patients consistently suffered exacerbations over time, while 
patients who did not have a history of exacerbations rarely had events during follow-up. As has 
been shown for COPD 54 and CF 55, a past history of exacerbations in patients with 
bronchiectasis is the strongest predictor of future events while individual co-morbidities, 
bacteriology, severity of radiological disease and other parameters explained only a very small 
amount of the variance in exacerbation rate.53 This suggests that we do not yet understand what 
leads a patient to be a frequent exacerbator and so in clinical practice the history of exacerbations 
is the only parameter we can confidently use for future prediction. 
Various studies have attempted to use statistical clustering techniques to identify 
subgroups of bronchiectasis patients with different characteristics.56, 57 Most clusters identified 
have been based on current age, age of onset of disease, and severity, and all have failed to 
replicate in independent cohorts suggesting they are not true phenotypes. The major phenotype 
that has been identified in all cohorts is patients chronically infected with P. aeruginosa.  
Patients with chronic infection by P. aeruginosa have an increased burden of disease including a 
higher frequency of exacerbations, worse health related quality of life, increased risk of hospital 
admissions and increased mortality.58-60 P. aeruginosa can exhibit adaptive behaviors allowing it 
to survive in a hostile environment such as the human airways; the production of biofilms 
obstructs exposure of bacteria to antibiotics and phagocytes.61, 62 P. aeruginosa also produces 
virulence factors that allow it to evade phagocyte killing and slow ciliary beat frequency, further 
allowing it to maintain its presence.63 However, the mere presence of P. aeruginosa has not been 
sufficient to define those patients who benefit from aerosolized suppressive antibiotic therapy8; 
since there are patients who do benefit from inhaled antibiotics6, this suggests there may be other 
factors (e.g. bacterial abundance) that are more predictive. 
There are patients who have “dry bronchiectasis”, in that they do not produce daily 
sputum, a syndrome long recognized; a case series published in the British Medical Journal in 
1933 describes 20 cases arising from infections in childhood where bronchiectasis was 
associated with cough and occasional hemoptysis without prominent sputum production. 64 Such 
patients have lower symptom scores but surprisingly have a higher mortality rate than patients 
who have chronic infection or daily sputum.56 Dry bronchiectasis has been classically associated 
with non-tuberculous mycobacterial (NTM) infection.   
In contrast, there is a group of patients who present with excessive sputum production but 
without the consistent finding of bacteria in sputum cultures.  Such patients have been described 
as having “sterile bronchorrhea” although modern molecular microbiology techniques teach us 
that sputum samples are never sterile.65 This group has been classically associated with 
inflammatory bowel disease where sputum samples contain neutrophils and necrotic material but 
do not have detectable pathogens.66 Further research is required to identify other meaningful 
clinical phenotypes that are independent of etiology. 
 
Microbiology and the microbiome 
Chronic bacterial infection is a characteristic feature of many patients with 
bronchiectasis. The term chronic infection is preferred to colonization as the latter implies a 
benign process whereas chronic infection is more reflective of the long-term interaction between 
microorganisms and the host leading to progressive tissue damage.  Sputum culture remains an 
important part of management because certain organisms have prognostic implications; this 
information can help guide treatment of exacerbations and may identify patients for whom long 
term suppressive antibiotic therapy may be effective.67 Traditional culture methods for bacteria 
show that nearly 80% of patients will regularly grow pathogens in sputum samples, the most 
frequent being Pseudomonas aeruginosa and Haemophilus influenzae but other Gram-negative 
(e.g. Moraxella catarrhalis, Escherichia sp. and Klebsiella sp) and Gram-positive (e.g. 
Streptococcus pneumoniae and Staphylococcus aureus) organisms are isolated with frequency.68 
Whereas H. influenzae and P. aeruginosa are the most common organisms in European studies, 
the US bronchiectasis registry reported high rates of isolation of NTM (50%) and P. aeruginosa 
(33%), while H. influenzae was relatively uncommon (8%).69 The reason for the higher 
frequency of NTM in the United States is not clear, but may reflect some element of selection 
bias as many US registry sites are also referral centers for NTM lung disease. 69 
Our understanding of chronic infection in bronchiectasis is evolving with the advent of 
sequencing technologies that allow a more comprehensive profiling of the bacterial communities 
in the lung (a.k.a. the microbiome). A microbiome analysis of healthy airways reveals a rich, 
diverse community of bacteria that are present in low abundance.70 It is premature to define a 
normal airways flora, as some (or all) of these could represent transient populations introduced 
through microaspiration.  Across a number of respiratory diseases it has been demonstrated that 
disease is associated with a loss of diversity, through the loss of important bacterial taxa, or by 
the dominance of a single or small group of taxa.71 The latter is referred to as a loss of evenness 
of the microbiota while the former is referred to as a loss of richness. Measures of richness and 
evenness, or composite diversity measures such as the Shannon-Wiener diversity index have 
been associated with lower lung function in bronchiectasis 72, although it cannot be stated 
whether this is causal or the result of frequent antibiotic exposure as studies to date have been 
mostly cross-sectional.  The proteobacteria which include Pseudomonas and Haemophilus come 
to dominate the diseased “dysbiotic” airway in bronchiectasis73 and have been associated with 
more neutrophil mediated inflammation and exacerbations.71 However, there is a subgroup of 
patients with microbiota dominated with firmicutes (e.g. the anaerobe Veillonella) that have 
frequent exacerbations despite lower levels of neutrophilic inflammation.74-76 
There is still much to learn about microbiota changes relevant to the development of 
bronchiectasis as well as its progression.  The importance of early persistent bacterial infection in 
CF and PCD is well established, but there is increased interest in persistent bacterial bronchitis in 
children that could lead to development of bronchiectasis, suggesting that aggressive treatment 
with antibiotis could ultimately prevent this from happening.77 Changes in the microbiome could 
also contribute to an exacerbation, there are changes in the microbiome as a consequence of 
antibiotic exposure, and after removal of the antibiotic exposure the microbiome can return to the 
prior state or remain altered (for better or for worse).  In addition, there may be species 
interactions that may influence their virulence and pathogenicity.78 Studies of microbiome 
changes have been inconsistent and may be more related to the individual.  Indeed, one study 
found very little change in composition of the microbiome over time despite antibiotic treatment 
and exacerbations.73 A long-term study of macrolide antibiotics (BLESS) demonstrated a 
decreased overall diversity of the microbiome and increase in the relative abundance of 
Pseudomonas as a result of the reduced relative abundance of other organisms sensitive to 
macrolides. 79 The clinical relevance of this observation is not known, but this was not associated 
with an increase in clinically relevant P. aeruginosa infections.  However, it suggests that 
antibiotic treatment may contribute to potentially pathogenic changes in the microbiota in some 
cases.   
While bacteria have received the most attention in microbiome studies, fungi and 
mycobacteria are also important in bronchiectasis. Aspergillus fumigatus is isolated in patients 
with advanced disease and in individuals with ABPA.  Aspergillus is the main different taxa 
between healthy controls and bronchiectasis patients and its abundance has been associated with 
exacerbations, suggesting that Aspergillus may be an important contributor to airway 
inflammation in some patients.80 In contrast the clinical significance of Candida albicans is less 
worrisome. It, too, is frequently isolated, and although some studies suggest a higher frequency 
of exacerbations in patients with Candida in sputum cultures, this may reflect reverse causation 
as Candida may be isolated after antibacterial treatment as a result of disturbance of bacterial 
microbiota.  
The majority of studies to date are inherently limited by the biases of current 
methodologies in that these microbiota studies do not adequately detect mycobacteria81, do not 
detect fungi or viruses, and underestimate some typical bacteria such as Staphylococci. Emerging 
metagenomics approaches allow comprehensive detection of bacterial, viral and fungal 
populations simultaneously, while also potentially providing data on the carriage of virulence 
genes and genes associated with antimicrobial resistance.82 Cost, technical and bioinformatics 
limitations are gradually being overcome to allow these studies to be performed more widely. 
 
Conclusions  
Ultimately clinical variables can only provide modest predictive accuracy for 
bronchiectasis outcomes and tell us nothing about the underlying biology of the disease. Recent 
progress in understanding genotypes and endotypes, the process of defining groups of patients by 
pathobiology often using biomarkers, is at an early stage in bronchiectasis but offer promising 
approaches to develop therapeutic interventions for some patients with bronchiectasis.  
Hopefully, in the near future we will have a standardized approach to the evaluation of patients 
with bronchiectasis, and will use genetic analyses and local and systemic biomarkers to stratify 
patients in terms of prognosis and therapy. 
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Figure and Table Legends 
Table 1. Clinical features associated with specific etiologies in bronchiectasis. Note that 
patients do not always present with classic features and therefore the absence of these signs 
cannot be used to exclude a specific etiology in bronchiectasis. Consensus guidelines 
recommend standardized testing irrespective of “clinical phenotype”. 
 
Figure 1. Model describing the pathogenesis of bronchiectasis.  A cycle of events that 
promote a persistent and progressive process over time. Impaired mucociliary clearance and 
retention of airways phlegm disrupt normal host defenses, renderings the airways vulnerable to 
infection, which can become persistent.  This, in turn, incites an inflammatory response causing 
injury and abnormal remodeling of the airways leading to bronchiectasis.   
 
Figure 2. CFTR mutation classification.  Cystic fibrosis transmembrane conductance 
regulators (CFTR) mutation classification based on molecular defect.  These molecular defects 
correspond to therapeutic approaches to restore the quantity of protein and/or its function 
resulting in genotype specific CFTR modulator drugs used alone (ivacaftor) or in combination 
(lumacaftor/ivacaftor, tezacaftor/ivacaftor). Adapted from 83 
 
Figure 3. Ciliary dyskinesia gene classifications.   Defects in cilia genes can be classified 
based on ultrastructural effects seen on cross sectional examination of cilia with electron 
microscopy. Note that some genes can be mutated without obvious structural abnormalities. 
Adapted from 84 
 
Figure 4. Potential endotypes for idiopathic bronchiectasis patients with pulmonary NTM 
infections. Characterization with biomarker measurements of sweat chloride, nasal NO, ciliary 
beat frequency, and body morphometrics coupled with the presence of relevant genetic variants 
may allow therapeutic targeting based on predominant endotype.  Examples would be the 
potential use of CFTR modulators in patients that have a CF-predominant endotype 85, sildenafil 
or other nitric oxide pathway agonists for cilia-predominant endotype 22, TGF-beta attenuators 
such as losartan for heritable connective tissue-predominant endotype 86, and immune 
modulators such as GMCSF for immune deficient predominant endotype 87 
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Figure 4. Potential endotypes for idiopathic bronchiectasis. 
 
 
 
 
  
  
 
